Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Translational Medicine|May 4, 2021
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparationsAndrea Gilg, Mirja Harms, Lia-Raluca Olari, et al.
Scientific Reports|September 30, 2020
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligandsMirja Harms, Andrea Gilg, Ludger Ständker, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 7, 2022
Virucidal activity of SARS-CoV-2 rapid antigen extraction buffersCarina Conzelmann, Tatjana Weil, Lia-Raluca Olari, et al.
International Journal of Molecular Sciences|December 11, 2022
Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma StabilityArmando Rodríguez-Alfonso, Astrid Heck, Yasser Bruno Ruiz-Blanco, et al.
Antiviral Research|August 2, 2020
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infectionCarina Conzelmann, Andrea Gilg, Rüdiger Groß, et al.
Communications Biology|September 23, 2021
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonistsPandian Sokkar, Mirja Harms, Christina Stürzel, et al.
Ebiomedicine|December 20, 2021
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variantsRüdiger Groß, Michelle Zanoni, Alina Seidel, et al.
Acta Pharmaceutica Sinica. B|September 30, 2021
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammationMirja Harms, Monica M W Habib, Simona Nemska, et al.
Journal of Medicinal Chemistry|November 8, 2023
Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma StabilityMirja Harms, Rikke Fabech Hansson, Andrea Gilg, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 11, 2022
Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2Rüdiger Groß, Lívia Mesquita Dias Loiola, Leila Issmail, et al.
Pageof 2